Younger patients with high-risk diffuse large B-cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOEP+I) in patients aged 18-60 years with DLBCL and age-adjusted internat...
E. Shumilov, M. Ziepert, B. Friedrichs et al.· British Journal of Haematolo...· 0 citations
Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients, while enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
E. Shumilov, Lina J. Kolloch, Philipp Faustmann et al.· Blood Advances· 0 citations
The data support recent recommendations advising treating patients with tandem transplantation regimes and support the idea that the optimal consolidation strategy remains to be defined.
Maria Dampmann, S. Flossdorf, Julius Keyl et al.· European Journal of Haematol...· 0 citations
In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.
M. Maulhardt, Lina J. Kolloch, G. Westhofen et al.· Clinical Lymphoma, Myeloma &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.